Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Enjoy this offer
* See conditions under "Our services"

Valuation: Appili Therapeutics Inc.

Capitalization 19.85L 14.26L 12.35L 11.33L 10.66L 14Cr 20.17L 1.35Cr 52.41L 6.57Cr 53.54L 52.38L 23Cr P/E ratio 2024
-1.12x
P/E ratio 2025 -1.62x
Enterprise value 1.31Cr 93.73L 81.17L 74.48L 70.08L 89Cr 1.33Cr 8.85Cr 3.45Cr 43Cr 3.52Cr 3.44Cr 150.22Cr EV / Sales 2024
14.9x
EV / Sales 2025 152x
Free-Float
99.94%
Yield 2024 *
-
Yield 2025 -
18/02 Appili Therapeutics announces closing of second tranche of non-brokered private placement RE
13/02 Appili Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2025 CI
18/12 Appili Therapeutics closes first tranche of non-brokered private placement RE
15/12 The Lundquist Institute and Vitalex Biosciences Announces Strategic Advancement of Second-Generation fungal Vaccine VXV-01 through Phase 1 Trials under $40 Million Competitive Contract from NIH/NIAID CI
14/11 Appili Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2025 CI
14/11 Appili Therapeutics Brief: On LIKMEZ (ATI-1501), Says "Building Commercial Momentum in the U.S. Through Re-Launch and Increasing Sales Growth" MT
14/11 Appili Therapeutics Brief: Citing New NIAID Non-Dilutive Funding Award of Up to US $40 Million with US$90 Million in Pending Proposals Across Multiple Infectious Disease Programs MT
14/11 Appili Therapeutics Brief: Reported a Q2 Net and Comprehensive Loss of $1.0 million ($0.01 per share) MT
05/11 Appili Therapeutics Announces $750,000 Private Placement for Working Capital, Drug Development MT
05/11 Appili Therapeutics announces proposed non-brokered private placement RE
05/11 Appili Therapeutics Brief: Announcing Proposed Non-Brokered Private Placement MT
05/11 Appili Therapeutics Inc. announced that it expects to receive CAD 0.75 million in funding CI
01/25/01 Appili Therapeutics Inc. and Vitalex Biosciences Wins Contract from NIAID Valued At Up to USD 40 Million to Develop Fungal Vaccine VXV-01 CI
3 months-25.00%
6 months-50.00%
Current year-40.00%
1 week 0.02
Extreme 0.015
0.02
1 month 0.02
Extreme 0.015
0.02
Current year 0.02
Extreme 0.015
0.02
1 year 0.01
Extreme 0.01
0.04
3 years 0.01
Extreme 0.01
0.08
5 years 0.01
Extreme 0.01
1.14
10 years 0.01
Extreme 0.01
1.89
Manager TitleAgeSince
Chief Executive Officer 65 01/11/2022
Director of Finance/CFO 68 16/11/2021
Corporate Officer/Principal - -
Director TitleAgeSince
Chairman 50 07/05/2015
Director/Board Member 58 01/10/2018
Chairman 59 13/11/2022
Date Insider Type Main position Quantity % Market Cap.
16/25/16Option

Director

1,28,674 0.1061%
16/25/16Option

Director

1,28,674 0.1061%
16/25/16Option

Director

11,89,580 0.9810%
Change 5d. change 1-year change 3-years change Capi.($)
0.00%0.00%0.00%-57.14% 14.26L
-0.37%+6.30%+48.66%+109.38% 5.5TCr
-0.58%-5.51%+50.00%+51.71% 4.34TCr
-1.31%-5.07%-20.12%-20.12% 2.23TCr
+1.31%-9.44%+35.85%+379.38% 2.04TCr
-7.21%-8.88%+23.25%-30.32% 1.73TCr
+1.74%-1.71%+7.76%-40.07% 1.5TCr
-1.93%+2.79%+20.42%+167.11% 1.32TCr
-2.90%-17.32%+12.88% - 1.17TCr
-2.13%-7.96%-32.93%+685.87% 1.15TCr
Average -1.35%-5.17%+14.58%+138.42% 2.1TCr
Weighted average by Cap. -1.11%-3.01%+27.13%+123.74%

Financials

2024 2025
Net sales 8L 6L 5L 5L 4L 5.66Cr 8L 56.12L 21.84L 2.74Cr 22.31L 21.83L 9.52Cr 1L 72.14T 62.47T 57.32T 53.93T 68.74L 1L 7L 3L 33.24L 3L 3L 1.16Cr
Net income -37.81L -27.15L -23.51L -21.58L -20.3L -26Cr -38.4L -2.56Cr -99.81L -13Cr -1.02Cr -99.74L -44Cr -26.25L -18.85L -16.32L -14.98L -14.09L -18Cr -26.66L -1.78Cr -69.29L -8.69Cr -70.78L -69.24L -30Cr
Net Debt 80.9L 58.1L 50.32L 46.17L 43.44L 55Cr 82.17L 5.49Cr 2.14Cr 27Cr 2.18Cr 2.13Cr 93Cr 1.11Cr 79.47L 68.82L 63.15L 59.42L 76Cr 1.12Cr 7.51Cr 2.92Cr 37Cr 2.98Cr 2.92Cr 127.37Cr
Logo Appili Therapeutics Inc.
Appili Therapeutics Inc. is a Canada-based biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures. The Company is advancing a diverse range of anti-infectives, including an FDA-approved ready-made suspension of metronidazole for the treatment of antimicrobial-resistant infections, a vaccine candidate to eliminate a serious biological weapon threat, and a topical antiparasitic for the treatment of a disfiguring disease. Its anti-infective product development portfolio includes three programs: LIKMEZ (ATI-1501), ATI-1701, and ATI-1801. ATI-1501 is its advanced commercial stage asset, a liquid oral taste-masked reformulation of the antibiotic metronidazole. ATI-1701 is a novel, live-attenuated vaccine for Francisella tularensis (F. tularensis). ATI-1801 is a novel topical formulation of paromomycin (15% w/w) under advanced clinical development for the treatment of cutaneous leishmaniasis, a disfiguring infection of the skin.
Employees
7
Date Price Change Volume
08/26/08 0.0150 $ 0.00% 1,65,000
05/26/05 0.0150 $ 0.00% 2,47,000
04/26/04 0.0150 $ -25.00% 41,436
03/26/03 0.0200 $ 0.00% 14,469
02/26/02 0.0200 $ +33.33% 2,74,330

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. APLI Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
BENEFIT NOW